Toprol-xl and Urinary retention - a phase IV clinical study of FDA data

Summary:

Urinary retention is reported as a side effect among people who take Toprol-xl (metoprolol succinate), especially for people who are male, 60+ old, also take Zometa, and have Multiple myeloma.

The phase IV clinical study analyzes which people have Urinary retention when taking Toprol-xl. It is created by eHealthMe based on reports of 38,273 people who have side effects when taking Toprol-xl from the FDA, and is updated regularly.

What is Toprol-xl?

Toprol-xl has active ingredients of metoprolol succinate. It is often used in high blood pressure. eHealthMe is studying from 40,636 Toprol-xl users. Check the latest studies of Toprol-xl.

What is Urinary retention?

Urinary retention (the inability to completely or partially empty the bladder) is found to be associated with 1,570 drugs and 1,740 conditions by eHealthMe. Check the latest studies of Urinary retention.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 16, 2026

38,273 people reported to have side effects when taking Toprol-xl.
Among them, 195 people (0.51%) have Urinary retention.

Could Toprol-xl cause Urinary retention?

Among these 195 people:

What is the gender of people who have Urinary retention when taking Toprol-xl? *

Click here to view

* Approximation only. Some reports may have incomplete information.

Do you take Toprol-xl and have Urinary retention?

- Check whether Urinary retention is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Toprol-xl:

Toprol-xl (40,636 reports)

Urinary retention treatments and more:

Urinary retention (42,974 reports)

How severe was Urinary retention and when was it recovered:

Urinary retention in Toprol-xl

Expand to all the drugs that have ingredients of metoprolol succinate:

Urinary retention and drugs with ingredients of metoprolol succinate (1,528 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Toprol-xl:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Urinary retention:

Urinary retention (1,570 drugs)

Browse all the conditions that are associated with Urinary retention:

Urinary retention (1,740 conditions)

Related publications that referenced our studies

Schattner A, Al-Bewerat A, "Levetiracetam (Keppra), urinary retention and literature search", A fatty cause of renal failure; what is your diagnosis?, 2016 Oct .
Schattner A, Al-Bewerat A, "Levetiracetam (Keppra), urinary retention and literature search", A fatty cause of renal failure; what is your diagnosis?, 2016 Oct .

How the study uses the data?

The study uses data from the FDA. It is based on metoprolol succinate (the active ingredients of Toprol-xl) and Toprol-xl (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.